Bulk modification assays are good at answering one kind of question: did the overall modification level shift? For a lot of early discovery work, that’s genuinely useful.

But once a study moves toward validating a biomarker or building a mechanistic case, “did it shift” stops being enough. The question becomes: shifted where? Which transcript, which position, which isoform? A modification event on one site of an mRNA can have a completely different functional consequence than the same modification a few bases away — and a bulk readout can’t distinguish between them.

This is where a lot of promising translational work stalls. Researchers have directional evidence — something is happening at the RNA modification level — but not the site-level resolution needed to defend that finding in a paper, a grant renewal, or a diagnostic validation study.

Site-specific, qPCR-based quantification closes that gap without requiring the sample volumes or turnaround times that LC-MS or NGS-based methods demand. You get an absolute number, tied to a specific position, generated on equipment your lab already runs.

The biology was always specific. The measurement should be too.